Success Stories: EB1-B Approval for Assistant Professor of Pharmaceutical Sciences in Illinois After Just 21 Days

On December 24, 2013, an Assistant Professor of Pharmaceutical Sciences in Illinois Received EB-1B Approval (Approval Notice)


General Field:  Pharmaceutical Sciences

Position at the Time of Case Filing:  Assistant Professor

Petitioner: Non-Profit Graduate and Professional School

National Origin: India

Service Center: Nebraska Service Center (NSC)

State Residing at the Time of Filing: Illinois

Approval Notice Date: 12/24/2013

Processing Time: 21 days


Case Summary:

We at North America Immigration Law Group – WeGreened.com have received EB-1B Outstanding Professors or Researchers approval for an Assistant Professor at a non-profit and professional school.  This client is an assistant professor of pharmaceutical sciences who has a strong background in the field, published 9 peer-reviewed scholarly articles, and has authored one book chapter. In addition to these publications, this client was invited to write 3 of the 6 review articles she has written, has been invited to present at 38 conferences, and to give 1 talk apart from these conferences. Moreover, this client’s work was cited 684 times at the time of filing the case, clearly showing that her work contributes to the field as a whole. This client’s research focuses on the drug delivery system, which further affects patients living with diseases, including cancer, malaria, skin disease, stroke, rheumatoid arthritis, and others. An independent recommender and expert in the field of Pharmaceutical Sciences, states: “[Client] has played a big role with it comes to the contribution of drug delivery systems to be administered intravenously, especially within the area of malaria.  She has found a new way to administer nanoparticles intravenously without having to worry about the occurrence of resistance or recrudescence of malarial incidence.  Her method of drug delivery also provides a way for the dosage frequency and intake to be lowered, making the cost of this treatment to be cheaper as a whole.” This EB-1B petition was approved in just 21 days.